Reflections on the emergence of chikungunya virus in the United States: Time to revisit a successful paradigm for the safety of blood-derived therapies

Transfusion

Volumn 55, Issue 1, 2015, Pages 224-226

  Farrugia, Albert ^a   Kreil, Thomas R ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SAFETY; BLOOD TRANSFUSION; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; DISEASE TRANSMISSION; HUMAN; INFECTION RISK; LETTER; RISK ASSESSMENT; UNITED STATES; ADVERSE EFFECTS; ASYMPTOMATIC DISEASE; BLOOD; BLOOD DONOR; CHIKUNGUNYA FEVER; COMMUNICABLE DISEASES, EMERGING; DONOR SELECTION; ECONOMICS; ISOLATION AND PURIFICATION; NUCLEIC ACID AMPLIFICATION; PROCEDURES; RISK REDUCTION; VIREMIA; VIROLOGY; VIRUS INACTIVATION;

ASYMPTOMATIC DISEASES; BLOOD DONORS; BLOOD SAFETY; BLOOD TRANSFUSION; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; COMMUNICABLE DISEASES, EMERGING; DONOR SELECTION; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RISK REDUCTION BEHAVIOR; UNITED STATES; VIREMIA; VIRUS INACTIVATION;

EID: 84920847887     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12933     Document Type: Letter

References (24)

1. Soucie JM, Richardson LC, Evatt BL, et al.; Hemophilia Surveillance System Project Investigators. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 2001; 41: 338-343.
2. Farrugia A,. The mantra of blood safety: time for a new tune? Vox Sang 2004; 86: 1-7.
3. European Medicines Agency. CPMP/BWP/268/95 Note for guidance on virus validation studies. 1996 [cited 2014 Oct 30]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003684.pdf.
4. Biggerstaff BJ, Petersen LR,. Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion 2003; 43: 1007-1017.
5. Petersen LR, Epstein JS,. Problem solved? West Nile virus and transfusion safety. N Engl J Med 2005; 353: 516-517.
6. Centers for Disease Control and Prevention (CDC). Fatal West Nile virus infection after probable transfusion-associated transmission-Colorado, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 622-624.
7. Kreil TR, Berting A, Kistner O, et al. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43: 1023-1028.
8. Food and Drug Administration. Guidance for industry. Use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion. 2009 [cited 2014 Oct 30]. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm189464.pdf
9. Fischer M, Staples JE,; Arboviral Diseases Branch, National Center for Emerging and Zoonotic Infectious Diseases, CDC. Notes from the field: chikungunya virus spreads in the Americas-Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep 2014; 63: 500-501.
10. Appassakij H, Khuntikij P, Kemapunmanus M, et al. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion 2013; 53: 2567-2574.
11. AABB. Chikungunya virus-Association Bulletin #14-03. 2014 [cited 2014 Jul 15]. Available from: http://www.aabb.org/programs/publications/bulletins/Docs/ab14-03.pdf
12. Prowse CV,. Component pathogen inactivation: a critical review. Vox Sang 2013; 104: 183-199.
13. McCullough J,. Pathogen inactivation: a new paradigm for blood safety. Transfusion 2007; 47: 2180-2184.
14. Leydold SM, Farcet MR, Kindermann J, et al. Chikungunya virus and the safety of plasma products. Transfusion 2012; 52: 2122-2130.
15. Tan LK, Lam S, Low SL, et al. Evaluation of pathogen reduction systems to inactivate Dengue and Chikungunya viruses in apheresis platelets suspended in plasma. Adv Infect Dis 2013; 3: 1-9.
16. Zou S, Stramer SL, Dodd RY,. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogenic donations. Transfus Med Rev 2012; 26: 119-128.
17. van der Poel CL, Janssen MP, Behr-Gross ME,. The collection, testing and use of blood and blood components in Europe 2008. Council of Europe, May 2011 [cited 2014 Jul 9]. Available from: http://www.edqm.eu/site/The-Collection-Testing-and-Use-of-Blood-and-Blood-3pdf-en-30141-2.html
18. European Medicines Agency. CPMP/BWP/390/97. The introduction of nucleic acid amplification technology (NAT) for the detection of hepatitis C virus RNA in plasma pools. London, July 1 1999. [cited 2014 Oct 30]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003613.pdf
19. Gallian P, de Lamballerie X, Salez N, et al. To the editor: prospective detection of chikungunya virus in blood donors, Caribbean 2014. Blood 2014; 123: 3679-3681.
20. Brouard C, Bernillon P, Quatresous I, et al.; workgroup "Quantitative Estimation of the Risk of Blood Donation Contamination by Infectious Agents." Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008; 48: 1333-1341.
21. Petersen LR, Epstein JS,. Chikungunya virus: new risk to transfusion safety in the Americas. Transfusion 2014; 54: 1911-1915.
22. Reddy HL, Doane SK, Keil SD, et al. Development of a riboflavin and ultraviolet light-based device to treat whole blood. Transfusion 2013; 53 (Suppl 1): 131S-136S.
23. Cerus Corporation. Partnership to initiate development of whole blood pathogen inactivation for sub-Saharan Africa. 2014 [cited 2014 Aug 26]. Available from: http://www.cerus.com/Investors/Press-Releases/Press-Release-Details/2014/Partnership-to-Initiate-Development-of-Whole-Blood-Pathogen-Inactivation-for-Sub-Saharan-Africa/default.aspx
24. Institute of Medicine. HIV and the blood supply-an analysis of crisis decision making., Leveton LB, Sox HC, Stoto MA, editors. Washington DC: National Academic Press; 1995. p. 15.